This review highlights the importance of screening, diagnosing, and treating peripheral arterial disease in patients with chronic kidney disease, a population in which PAD is often overlooked despite being a strong cardiovascular risk factor.
Answers are grounded in this paper and cite their sources.
May support routine PAD screening in CKD; extends awareness but leaves randomized outcome trials open.
Cardiovascular disease is a major source of morbidity and mortality for patients with chronic kidney disease (CKD). Peripheral arterial disease (PAD) is a strong predictor of coronary artery disease and a risk factor for mortality in the general population. This is of particular interest to nephrologists because the risk for PAD is increased in CKD. Often, PAD is overlooked as a source of morbidity and as a cardiovascular risk factor in this population. This review serves as an overview of the epidemiology, screening, diagnosis, and treatment of PAD with an emphasis on CKD.
No takes yet. Share an insight, caveat, or question.
DeLoach et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: